Pharmatech Associates, a USP company’s Post

The pharmaceutical supply chain vulnerabilities and challenges exposed by the COVID-19 pandemic resulted in widespread drug shortages and disruptions. Although certain aspects of the pandemic have subsided, drug shortages have persisted on a global scale. The demand for flexibility in supply chains remains imperative, yet many drug manufacturers hesitate to make significant changes to their processes and facilities due to regulatory hurdles, differing expectations, and implementation timelines that may be imposed by global regulatory changes. Fortunately, regulatory bodies have recognized the pressing need to fortify and streamline supply chains. Collaborative efforts among global regulators are underway to address challenges related to drug availability, with some promising initiatives currently in the pilot phase. CAI, Connie Leech, Geraldine Carr-Mulry Pharmaceutical Online

FDA’s drug promotion watchdog plans study around adherence claims in pharma ads >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #productmarketing #biotech #healthcare #pharmaceutical

FDA’s drug promotion watchdog plans study around adherence claims in pharma ads >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #productmarketing #biotech #pharmaceutical #pharma

This could have a major impact on pharmaceutical drug development leading to more efficiencies and reduced regulatory burden! Especially for #emergingbiopharma companies whose platform enables them to target multiple indications/pathologies, but are operating in an uncertain funding environment. So when a company might have to otherwise focus its resources on only the most probable disease indications, this updated guidance from the #USFDA could mean more drugs reaching more patients who need them - as safe and effective therapeutic platforms move through the clinics more rapidly.

🔬 The Pharma Industry faces complex regulatory challenges and scrutiny while striving to maintain patient safety and innovation. This Industry Outlook Report for 2023, addresses these challenges and aims to assist businesses in navigating the evolving regulatory landscape and mitigating emerging risks. Compliance with these updates will require increased transparency and a focus on supply chain agility. 🌱ESG considerations are vital for the pharmaceutical industry in 2023. This report will help you navigate the evolving pharmaceutical landscape and ensure a sustainable future for your business by providing key actionable steps. 📥 Download the Pharma report from Ethixbase360 today: https://lnkd.in/eSmePRED #PharmaceuticalIndustry #Pharma #RegulatoryCompliance #ESGConsiderations #ESG #SupplyChain #Ethixbase360 #DueDIligence #Reporting #Environmental #Sustainability #LifeSciences #Pharmaceutical #Governance #RiskManagement #pharmaceutical #pharmareport #pharmaindustry

The Pharmaceutical Track and Trace System, branded as #DrugXafe, is an excellent digital platform in Türkiye that ensures the #safety and #reliability of drug distribution. By assigning a unique #2DDataMatrix to every drug box and logging it into an electronic #database, The Pharmaceutical Track & Trace System (PTSS) enhances patient safety by providing real-time tracking of drugs to prevent the circulation of counterfeit drugs. It supports all healthcare stakeholders, from manufacturers to pharmacies, enhancing drug safety and supply chain efficiency. Through its innovative approach, DrugXafe not only secures the drug #supplychain but also sets a new standard in pharmaceutical industry practices. As we try to maintain the integrity of healthcare, DrugXafe demonstrates excellence in pharmaceutical safety and clean supply chain management. With DrugXafe Mobile App, even end-users can access detailed drug information on-demand, ensuring drugs are genuine and safe directly from their smartphones. With DrugXafe's robust and transparent processes ensuring drug safety and building trust, let's shape the future of healthcare together! #Tiga #HealthcareIT #PharmaIT #DrugXafe

Unapproved uses of approved drugs: FDA lays out pharma considerations for informing providers >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #healthcare #pharma #productmarketing #pharmaceutical

How generic drug sponsors can ask FDA to reconsider applications: new draft guidance explains >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #biotech #productmarketing #healthcare #pharmaceutical

On May 31, 2024, #China's National Healthcare Security Administration (NHSA) announced the issuance and implementation of the Procedures for Determining the Inclusion of Drugs in the National #Reimbursement Drug List📋 (Trial) (hereinafter referred to as "Procedures").   The Procedures address cases in which discrepancies arise in the names or dosage forms of drugs, such as those caused by renaming, which differ from the listings in the #NRDL. In these instances, stakeholders believe that, according to the NRDL's related provisions, these drugs should be identified as either included in or excluded from the NRDL.   The determination process involves four key stages: application submission, application confirmation, expert review, and result publication.   Further reading at👇 https://lnkd.in/gCPPQVkr #pharmaceutical #pharmaceuticalindustry #regulations